Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "CT P6 Celltrion"

03:05 EDT 30th July 2014 | BioPortfolio

Matching Channels

None

Matching News

A second lawsuit tests the BPCIA biosimilars ‘patent dance’ waters

By Kurt R. Karst –        Earlier this week, Celltrion Healthcare Co., Ltd. and Celltrion, Inc. (collectively “Celltrion”) filed a Complaint for Declaratory Judgment in the U.S. District...

Celltrion, Inc. - Product Pipeline Review - 2014

Celltrion, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Celltrion, Inc. - Product Pipeline Review - 2014’, provides an overview of the Celltrion, Inc.’s pharmaceutic...

S. Korea's Celltrion says top shareholder drops plan to sell stake

SEOUL, July 2 (Reuters) - Celltrion Inc said on Wednesday its top shareholder is no longer considering a sale of a stake in the biotechnology company.

Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade

Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.

Celltrion to target US next for Remicade biosim approval

Following a Japanese approval last week Celltrion and partner Nippon Kayaku have claimed the US as the next target market for their Remicade (infliximab) biosimilar.

Celltrion files suit to clear U.S. path for biosimilar Remicade

Celltrion Inc. (KOSDAQ:068270) filed suit in the U.S. District Court for the District of Massachusetts seeking a declaratory judgment that three patents from Johnson & Johnson (NYSE:JNJ) covering the...

Celltrion files infliximab patent lawsuit in US

South Korean biotechnology company Celltrion filed a lawsuit on 31 March 2014 in a federal court in Massachusetts seeking a declaratory judgement that Janssen Biotech’s (Janssen) remaining patents o...

Celltrion Eyes U.S. As Next Target For Remicade Biosimilar Approval

South Korea’s Celltrion and Japanese partner Nippon Kayaku eye the U.S. for the next approval of their biosimilar of Johnson & Johnson’s Remicade.

Matching PubMed Articles

None

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement